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inTrOducTiOn
The production of human monoclonal mAbs for research and 
clinical use is closely related to the development of phage 
display technology, initially described by Smith in 1985 and 
further developed by other groups (e.g., Winter, McCafferty, 
Lerner, Barbas). Antibody phage display (APD) is based on 
genetic engineering of bacteriophages (viruses that infect 
bacteria) and repeated rounds of antigen-guided selection 
and phage propagation (Barbas, 2001). This technique allows 
in vitro selection of mAbs of virtually any specificity, greatly 
facilitating recombinant production of reagents for use in 
research and clinical diagnostics, as well as for pharmaceu-
ticals for therapeutic use in humans (e.g., adalimumab, the 
first fully human APD-derived mAb) (Lee et al., 2007).
Because of a physical connection established between the 
antibody fragment on the outside and the genetic informa-
tion encoding the displayed protein within the phage, APD 
also allows comprehensive studies of genetics and function 
of antigen-specific mAbs. These characteristics make APD a 
powerful tool to better understand immunological processes 
and human diseases that involve formation of (auto-)antibod-
ies against defined (self-)antigens.
anTiBOdY-liBrarY preparaTiOn
The APD process begins with antibody-library preparation, 
followed by ligation of the variable heavy (VH) and variable 
light (VL) PCR products into a phage display vector, culmi-
nating in analysis of clones of mAbs. A large antibody library 
and efficient selection are needed to isolate specific mAbs 
from a cloned immunoglobulin repertoire. The key to suc-
cess is preparation of quality RNA from the cell source cho-
sen (e.g., peripheral blood mononuclear cells). This RNA is 
reverse-transcribed into cDNA, which is used for PCR of the 
VH and VL chains of the encoded antibodies (Figure 1a, b). 
Defined sets of primers specific for the different VH and VL 
chain–region gene families then allow amplification of all 
transcribed rearranged variable regions within a given immu-
noglobulin repertoire for library construction, thus reflect-
ing all antibody specificities in a particular individual. This 
immortalizes recombinant cDNA clones for expressed Igs. 
Variations on phage display libraries include (i) libraries con-
structed for Ig isotypes (e.g., IgG, IgA, and IgE) and (ii) librar-
ies of mAbs expressed as Fab fragments or as single-chain 
variable fragments (scFv), the latter of which consist of the 
VH and VL joined by a linker (Figure 1b).
phaGe and phaGemid BiOlOGY in apd
The VH and VL PCR products, representing the antibody 
repertoire, are ligated into a phage display vector (e.g., the 
phagemid pComb3X) that is engineered to express the VH 
and VL as an scFv fused to the pIII minor capsid protein of a 
filamentous bacteriophage of Escherichia coli that was origi-
nally derived from the M13 bacteriophage. However, the 
phage display vector pComb3X does not have all the other 
genes necessary to encode a full bacteriophage in E. coli. 
For those genes, a helper phage is added to the E. coli that 
WHAT ANTIBODY PHAGE DISPLAY DOES
•  Antibody phage display (APD) allows in vitro 
selection of human mAbs of virtually any specificity 
and affinity.
•  Owing to its design, this technique permits 
both genetic and functional analyses of the mAb 
selected, thus facilitating studies on mechanisms of 
the human immune system.
•  Translational research approaches embracing APD 
may converge on new future therapies.
LIMITATIONS 
•  Phage display may not recover all antigen-specific 
mAbs present in a given antibody library.
•  The heavy- and light-chain pairing may not reflect 
that of the in vivo immunoglobulin.
•  APD is a complicated, demanding, and time-
consuming technology. 
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to antigen (immobilized on ELISA plates or in solution on cell 
surfaces), washing, elution, and reamplification of the phage 
binders in E. coli (Figure 1a). During each round, specific 
binders are selected out from the pool by washing away non-
binders and selectively eluting binding phage clones. After 
three or four rounds, highly specific binding of phage clones 
through their surface mAb is characteristic for directed selec-
tion on immobilized antigen. For panning on eukaryotic cell 
surfaces, more rounds of panning are usually needed, and 
more sophisticated protocols involving cell-sorting tech-
niques have been published (Barbas, 2001). Of note, it is also 
possible to perform double recognition panning to select for 
bispecific mAbs (i.e., mAbs that recognize two antigens), 
as demonstrated in a patient with active mucocutaneous 
pemphigus vulgaris (PV) and serum antibody reactivity against 
desmoglein (Dsg) 3 and Dsg1, yielding scFv specific for both 
Dsg3 and Dsg1 (Payne et al., 2005).
FuncTiOnal and GeneTic analYsis OF selecTed maBs
After cyclic panning, the resultant (polyclonal) phage pools 
(i.e., a mixture of all the phages that bind to the antigen 
chosen) are tested by phage ELISA, in which the phage pool 
are transformed with the phage display vector library. The 
result is a library of phages, each expressing on its surface a 
mAb and harboring the vector with the respective nucleotide 
sequence within (Figure 1c).
In addition to the ability to produce phage displaying the 
mAb, the phage display vector can be used to produce the 
mAb itself (not attached to phage capsid proteins) in cer-
tain strains of E. coli. Additional cDNA is engineered, in the 
phage display vector, after the VL and VH sequences to allow 
characterization and purification of the mAb produced. 
Specifically, the recombinant antibody may have a hemag-
glutinin (HA) epitope tag and a polyhistidine to allow easy 
purification from solution (Barbas, 2001).
FindinG The needle(s) in The haYsTacK: selecTiOn
BY panninG
Diverse APD libraries are produced from ~108 independent 
E. coli transformants infected with helper phage. A library is 
screened for phage binding to an antigen through its expressed 
surface mAb by a technique called (bio-)panning. Cyclic pan-
ning allows for pulling out potentially very rare antigen-bind-
ing clones and consists of multiple rounds of phage binding 
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Figure 1. antibody phage display (apd). (a) Diagram showing how APD is performed. (b) Interrelatedness of Ig (here, IgG), single-chain variable fragment 
(scFv), and Fab. Importantly, both scFv and Fab reflect the original specificity of the Ig they are derived from because variable heavy (VH) and variable light 
(VL) chains form the interface with the antigen. (c) Phage display systems are derived from wild-type bacteriophage of Escherichia coli. Monovalency of the 
displayed protein (turquoise) ensures selection for high-affinity mAbs in phagemid vector-based systems (e.g., pComb3X). Helper phages display a fusion 
protein as well after propagation from phage-infected cells and are also selected during panning (but they do not possess the sequence of the displayed protein 
within). A defective helper phage origin of replication ensures preferential production and packaging of the desired phage particles, requiring addition of new 
helper phage in every panning round.
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is incubated on an antigen-coated plate and then, after 
being washed, developed with an enzyme-conjugated anti-
phage antibody directed against the major capsid protein 
and a chromogenic substrate specific for the enzyme cho-
sen. If these pools bind the desired antigen (compared with 
control nonpanned phage libraries), the enzyme renders a 
change in color, indicating enrichment of phage binding 
of the specific antigen. In that case, E. coli infected with 
polyclonal phage is plated out and individual colonies are 
picked and expanded for monoclonal phage production. 
These are each tested again by phage ELISA to confirm anti-
gen binding. The phage display vector, isolated from each 
clone, is then subjected to sequencing to determine the 
nucleotide sequence of VL and VH encoding the mAb that 
bound to the antigen. Furthermore, soluble scFv (or Fab) 
from clones of interest can easily be produced in bacteria 
that have been transformed with the phage display vector 
of interest. These mAb are then purified by metal chela-
tion (e.g., through polyhistidine) or affinity purification 
(e.g., through a HA tag). To further analyze these soluble 
mAbs, a vast array of methods exists (Figure 1a). Obtained 
nucleotide sequences can be analyzed and grouped (e.g., 
by heavy- or light-chain gene usage and shared “finger-
prints,” known as complementarity-determining region 3, 
indicating common B-cell clonal origin) with tools avail-
able online (e.g., VBASE2 and IMGT/V-QUEST).
applicaTiOns OF apd in inVesTiGaTiVe dermaTOlOGY
Despite the power to genetically and functionally char-
acterize antibody responses, APD has been used in only 
a few studies to mechanistically dissect human skin dis-
eases, perhaps because it is a demanding technology. Ishii 
et al. (2008) applied APD to characterize the IgG coding 
sequences from a pemphigus foliaceus (PF) patient and 
obtained, after cyclic panning against Dsg1, five Dsg1-
specific IgG heavy-chain clones with restricted VH gene 
usage. Two of these five anti-Dsg1 clones proved pathogen-
ic, meaning that the antibodies recombinantly produced 
from their nucleotide sequences caused typical PF blister 
formation in human skin (Figure 2). Inhibition ELISA stud-
ies using a pathogenic scFv derived from these clones and 
multiple PF sera suggested that the pathogenic antibody 
response in other PF patients is directed at similar or identi-
cal Dsg1 epitopes as defined by the clones’ scFv from this 
patient (Figure 3), also illustrating the biological validity of 
studying human disease with monoclonal scFv. Yamagami 
et al. (2009) reported similar findings with another PF 
patient, and comparable results have also been obtained 
by APD of PV patients’ peripheral blood mononuclear cells 
(Payne et al., 2005).
Similarly, Saleh et al. (2012) cloned pathogenic anti-
Dsg3 mAbs from a patient with paraneoplastic pemphigus 
and found four Dsg3-specific clones (profoundly restricted 
to the VH1 family), of which three were pathogenic. Further 
characterization of those scFv (and the patients’ serum 
antibodies) using a series of Dsg3/Dsg2 domain-swapped 
molecules and immunoprecipitation demonstrated that the 
epitopes covered extracellular domains (EC) 1–4, in con-
trast to classical PV in which pathogenic abs mostly bind to 
EC1–2 (Figure 4).
In a translational research approach designed to use a 
nonpathogenic cloned scFv from a pemphigus patient to 
deliver a biologically active agent to the epidermis, Kouno 
et al. (2013) created a fusion protein containing Px44, a 
nonpathogenic anti-Dsg-scFv domain (Payne et al., 2005), 
linked to an active domain of human tumor necrosis factor–
related apoptosis-inducing ligand (hTRAIL). The recombi-
nantly produced Px44-hTRAIL fusion protein bound and 
delivered TRAIL to the cell surface of human keratinocytes 
(Figure 5a). The TRAIL component maintained its known 
biological activity both to inhibit secretion of γ-interferon 
by activated CD4+ T cells and to cause apoptosis of 
Figure 2. monovalent mabs (in the form of scFv) cause blister formation 
typical of pemphigus foliaceus in human skin. After injection of purified 
antidesmoglein 1 scFv, human skin specimens were cultured for 24 hours. 
Histology and direct immunofluorescence (IF) are shown. 3-07/1e and 
3-30/3h caused superficial epidermal blisters. All scFv, except 3-094/O1808, 
bound to the cell surface of epidermal keratinocytes. Immunoprecipitation 
and indirect IF experiments suggested that 3-094/O1808 binds to the 
proprotein but not to the mature protein (data not shown). mAb, monoclonal 
antibody; scFv, single-chain variable fragment. Reprinted with permission 
from Ishii et al. (2008).
Figure 3. multiple pF and pV sera compete for the same or nearby epitopes 
targeted by an anti-dsg-1 monoclonal scFv (3-30/3h) derived from a pF 
patient. 6 PF sera, 5 mucocutaneous PV sera, and 3 mucosal PV sera (and a 
normal control, N) were used to block binding of the 3-30/3h to Dsg1. All PF 
and mucocutaneous PV sera inhibited binding of 3-30/3h, but mucosal PV 
patients’ sera (featuring anti-Dsg3 antibodies only) did not. Dsg, desmoglein; 
PF, pemphigus foliaceus; PV, pemphigus vulgaris; scFv, single-chain variable 
fragment. Reprinted with permission from Ishii et al. (2008).
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rapidly proliferating lymphocytes and keratinocytes. In 
a preliminary study Px44–hTRAIL caused apoptosis in a 
mouse model of actinic keratosis and early squamous-cell 
carcinoma (Figure 5b). These studies suggest that mAbs 
cloned from pemphigus patients may be useful as agents 
to deliver biologically active proteins to the epidermis for 
therapy of various immunological and neoplastic diseases.
Figure 4. Three anti-dsg3 scFvs (pnp-a1/B1/c1) isolated from a pnp 
patient bind to the ec2 and ec3 domains of dsg3 in immunoprecipitation/
immunoblot analysis of the patient’s and a pV patient’s sera. The PNP patient’s 
sera recognized Dsg3 epitopes EC1–4, but the mAbs derived by phage display 
recognized only EC2 and EC3. In classic PV patients, the main epitopes are EC1 
and EC2. These findings also demonstrate that antibody phage display may miss 
some pathologic clones (here, such mAbs that target EC1 and EC4) for various 
reasons, as discussed in the last paragraph of this article. Dsg, desmoglein; PNP, 
paraneoplastic pemphigus; PV, pemphigus vulgaris; scFv, single-chain variable 
fragment. Reprinted with permission from Saleh et al. (2012).
limiTaTiOns and peculiariTies
Compared to other methods used to dissect human immune 
responses (Table 1), APD offers sufficient depth of coverage to 
find antigen-specific mAbs even if they are rare in the ab-coding 
repertoire of circulating cells. The relative ease of construct-
ing and screening antibody libraries comes from many well-
established published protocols, and there are various easily 
Figure 5. px44-hTrail binds to human epidermal keratinocytes and causes 
apoptosis of tumor cells. (a) When injected intradermally into human skin, the 
fusion protein binds to the cell surface of epidermal keratinocytes as detected 
by immunofluorescence with anti-hemagglutinin (HA) and anti-hTRAIL 
antibodies. (b) TUNEL staining of actinic keratosis-like lesions in K14-activated 
Fyn transgenic mice after intratumoral injection of the fusion protein shows 
apoptosis of tumor cells (green fluorescence signal). hTRAIL, human tumor 
necrosis factor–related apoptosis-inducing ligand. Reprinted with permission 
from Kouno et al. (2013).
Table 1. Other typical methods used for studies characterizing the genetics of human (auto-)antibody responses
method production of mab sequencing selection bias1 advantages disadvantages
Antibody phage 
display
scFv, Fab  
(Ig)
Directly from 
phage display 
vector
+ Relative ease of screening, 
sequencing, and production 
of soluble protein; depth of 
coverage; ease of adapting 
isotype-specific applications 
Random pairing of VH and 
VL, tedious Ig production 
(subcloning required)
Heterohybridoma Ig RT-PCR + In vivo VH/VL pairing, 
production of full-length Ig
EBV/unselected fusions 
often yield IgM, instability 
phenomena and inefficient 
isolation, expensive culturing
Single B-cell PCR (Ig) RT-PCR + In vivo VH/VL pairing Difficult mAb production 
(subcloning), difficult for  
rare clones
Deep sequencing None From any nucleo-
tide source
– No selection bias, calculation 
of frequencies
Necessary trade-off of 
sequencing length and read 
number; no pairing of VH  
and VL for analysis
Advancements and combinations of the methods detailed above may pave the way for future studies of unparalleled depth and accuracy (see DeKosky et 
al., 2013, and others).
EBV, Epstein–Barr virus; scFv, single-chain variable fragment; VH, variable heavy; VL, variable light.
1Selection bias may result from differences in phage growth rates, instability of cell fusions, or limited numbers of B cells analyzed by single B-cell PCR. 
These effects may lead to nonrepresentative (biased) distributions of the parameters analyzed.
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accessible systems that facilitate production of soluble mAbs. 
Still, there are limitations to APD. One example is that pairing 
of VH and VL chains during phage display library construc-
tion may not represent the in vivo antibody pairing in patients. 
However, scFvs derived from APD bind the same epitopes on 
Dsg as polyclonal patient IgGs do (Figure 3), and some data 
indicate that in both heterohybridoma and APD the same genes 
for VH and VL are detected (unpublished observation), suggest-
ing that the mAbs derived from APD accurately represent the 
antibodies in patients. A second caveat is that APD libraries may 
not fully represent all antibodies, because not all phage clones 
of a given library will display a protein because of inherent tox-
icity or interference with phage assembly. A third issue is that 
clones of interest may be missed as a result of poor recovery of 
RNA from cells or from loss of DNA during library construction, 
which requires repetitive gel purifications. Finally, undersized 
sampling of monoclonals after panning may result in the loss 
of some relevant clones. However, even given these limita-
tions, APD—by virtue of its ability to screen up to 1012 phages to 
select those with antigen binding—is thought to be much more 
likely to detect relevant antibodies than are cell-based methods, 
whose numbers are much more limited. Combination of APD 
with other established high-throughput methods such as next-
generation sequencing and/or proteomics may offer the most 
powerful approach for future molecular deciphering of antigen-
specific serum responses in disease and health (Cheung et al., 
2012; DeKosky et al., 2013; Wine et al., 2013).
CONFLICT OF INTEREST
J.R.S. holds a US patent (8,470,323) on parts of the technologies described herein.
CME ACCREDITATION
This CME activity has been planned and implemented in accordance with 
the Essential Areas and Policies of the Accreditation Council for Continuing 
Medical Education through the Joint Sponsorship of ScientiaCME and 
Educational Review Systems. ScientiaCME is accredited by the ACCME 
to provide continuing medical education for physicians. ScientiaCME 
designates this educational activity for a maximum of one (1) AMA PRA 
Category 1 Credit™. Physicians should claim only credit commensurate with 
the extent of their participation in the activity.
To take the online quiz, follow the link below: 
http://www.classmarker.com/online-test/start/?quiz=kja529668ecdcb7e
ACKNOWLEDGMENTS
This work was supported by a research fellowship from the DFG (HA6736/1-1) to 
C.M.H., and by grants R01-AR052672 and P30-AR057217 from the National 
Institute of Arthritis and Musculoskeletal and Skin Diseases, National 
Institutes of Health to J.R.S. We thank Aimee S. Payne for providing us with an 
earlier version of Table 1.
SUPPLEMENTARY MATERIAL
A PowerPoint slide presentation appropriate for journal club or other teaching 
exercises is available at http://dx.doi.org/10.1038/jid.2013.521.
REFERENCES
Barbas CF (2001) Phage display: a laboratory manual. Cold Spring Harbor 
Laboratory Press: Cold Spring Harbor, NY
Cheung WC, Beausoleil SA, Zhang X et al. (2012) A proteomics approach for 
the identification and cloning of monoclonal antibodies from serum. Nat 
Biotechnol 30:447–52
DeKosky BJ, Ippolito GC, Deschner RP et al. (2013) High-throughput 
sequencing of the paired human immunoglobulin heavy and light chain 
repertoire. Nat Biotechnol 31:166–9
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D.  Desired production of full-length immuno-
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